Search alternatives:
significant linear » significant clinical (Expand Search), significant gender (Expand Search), significant level (Expand Search)
linear decrease » linear increase (Expand Search)
better decrease » greater decrease (Expand Search), teer decrease (Expand Search), between decreased (Expand Search)
significant linear » significant clinical (Expand Search), significant gender (Expand Search), significant level (Expand Search)
linear decrease » linear increase (Expand Search)
better decrease » greater decrease (Expand Search), teer decrease (Expand Search), between decreased (Expand Search)
-
381
-
382
-
383
-
384
ECoG timescales decrease during spatial attention.
Published 2025“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”
-
385
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
386
-
387
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
388
-
389
-
390
-
391
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
392
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
393
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
394
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
395
-
396
-
397
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
398
-
399
-
400